Clinical application of ultrasound-guided percutaneous microwave ablation in the treatment of T1aN0M0 stage renal carcinoma.

Evaluation of clinical application of ultrasound-guided percutaneous microwave ablation treatment for T1a renal carcinoma.

Analysis of the clinical data from 31 patients with T1aN0M0 stage renal carcinoma who underwent ultrasound-guided percutaneous microwave ablation in the Department of Ultrasound of China-Japan Union Hospital of Jilin University between March 2010 and June 2014.

All of the 31 patients were treated with ablation only once: 96.8% (30/31) of patients had no local recurrence or distant metastasis after ablation. One (3.2%) patient had local tumor recurrence 6 months after surgery and underwent a second microwave ablation. According to the results of 2 years of follow-up re-examinations, no further recurrence or distant metastasis was found. Moreover, 90.3% (28/31) of the patients had no complications with normal ranges of preoperative and postoperative serum creatinine and urea nitrogen levels. Complications were found in 9.7% (3/31) of the patients: one case of transient hematuria, one case of perirenal hematoma, and one case of cholecystitis; the symptoms were resolved with symptomatic treatment.

Ultrasound-guided percutaneous microwave ablation is a safe and effective micro-invasive therapy for T1a renal cancer patients.

Journal of medical ultrasonics (2001). 2018 Dec 18 [Epub ahead of print]

Guoqing Sui, Qiang Luo, Jiarui Du, Dengke Teng, Hui Wang

Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, 130000, Jilin, China., Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, 130000, Jilin, China. .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe